Pain News and Research

Latest Pain News and Research

FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

The Federation of American Societies for Experimental Biology has honored Samuel M. Young, Jr. Ph.D., a Max Planck Research Group Leader at Max Planck Florida Institute for Neuroscience, with the Glaxo Smith Kline Neuroscience Discovery Award.

23 Jun 2015

Roche unveils series of new diagnostic technologies at EuroMedLab

Today at the 21st annual meeting of the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Paris, France, Roche unveiled a series of new diagnostic technologies.

23 Jun 2015

New research could help reverse side effects of acetaminophen overdose

New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines.

23 Jun 2015

Opioid offers pain relief for Parkinson’s patients

Prolonged-release combined oxycodone/naloxone may provide relief for patients with severe pain related to Parkinson’s disease, a double-blind randomised trial shows.

22 Jun 2015

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 5mg/ 5ml of Oxycodone HCl liquid which is used in treatment of moderate to severe acute and chronic pain. Wockhardt is launching the product soon and will be amongst the few generic versions of this product in the market.

22 Jun 2015

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.

22 Jun 2015

New research sheds light on molecular architecture of receptors linked to many brain diseases

Scientists at The Scripps Research Institute have teamed up with several other institutions and pharmaceutical companies, including the University of Southern California (USC), San Diego's Receptos Inc. and Japanese company Ono Pharmaceutical Co., Ltd., to publish the first 3D structures of a receptor implicated in many diseases of the brain and in normal physiology throughout the body.

22 Jun 2015

TSRI scientists devise powerful set of chemical methods to explore protein biology

Scientists at The Scripps Research Institute (TSRI) have devised a powerful set of chemical methods for exploring the biology of proteins.

22 Jun 2015

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API).

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

19 Jun 2015

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.

19 Jun 2015

Effective medical communication missing between physicians and patients with chronic migraine

Many patients with chronic migraine (CM) receive suboptimal medical treatment even when they seek medical care. Reporting at the annual scientific meeting of the American Headache Society, researchers found that the majority of clinical encounters between CM patients and physicians were missing essential components of effective communication.

19 Jun 2015

New study launched in Liberia to better understand health consequences of Ebola virus disease

The Liberia-U.S. clinical research partnership known as PREVAIL has launched a study of people in Liberia who have survived Ebola virus disease (EVD) within the past two years. The study investigators hope to better understand the long-term health consequences of EVD, determine if survivors develop immunity that will protect them from future Ebola infection, and assess whether previously EVD-infected individuals can transmit infection to close contacts and sexual partners.

18 Jun 2015

Findings could lead to treatments for chronic pain caused by nerve damage

Non-narcotic treatments for chronic pain that work well in people, not just mice, are sorely needed. Drawing from human pain genetics, an international team led by Boston Children's Hospital demonstrates a way to break the cycle of pain hypersensitivity without the development of addiction, tolerance or side effects.

18 Jun 2015

Scientists explain the existence of intrinsic chirality in ordinary nanocrystals

A team of scientists from ITMO University and Trinity College Dublin published first experimental results showing that ordinary nanocrystals possess intrinsic chirality and can be produced under normal conditions as a half-and-half mixture of mirror images of each other.

18 Jun 2015

Identifying obstructive coronary artery disease in women: an interview with Dr. Ladapo, NYU School of Medicine

A recent study presented at the American College of Cardiology 64th Annual Scientific Meeting evaluated the impact of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients suggestive of CAD in the outpatient setting.

17 Jun 2015

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

Low heart rate variability may place women at risk for sexual dysfunction

Chances are good that women with a low heart rate variability also suffer from sexual dysfunction. That's the finding from a study led by Amelia Stanton of The University of Texas at Austin in the US published in Springer's journal Applied Psychophysiology and Biofeedback.

17 Jun 2015

Pain News and Research

Latest Pain News and Research

FASEB honors Max Planck Florida scientist with Glaxo Smith Kline Neuroscience Discovery Award

Roche unveils series of new diagnostic technologies at EuroMedLab

New research could help reverse side effects of acetaminophen overdose

Opioid offers pain relief for Parkinson’s patients

Wockhardt obtains final approval from FDA for marketing 5mg/ 5ml of Oxycodone HCl liquid

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

New research sheds light on molecular architecture of receptors linked to many brain diseases

TSRI scientists devise powerful set of chemical methods to explore protein biology

ScinoPharm Taiwan, Raffles PharmaTech collaborate to manufacture Celecoxib

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

Lilly announces positive results from LY2951742 Phase 2b study in patients with episodic migraine

Effective medical communication missing between physicians and patients with chronic migraine

New study launched in Liberia to better understand health consequences of Ebola virus disease

Findings could lead to treatments for chronic pain caused by nerve damage

Scientists explain the existence of intrinsic chirality in ordinary nanocrystals

Identifying obstructive coronary artery disease in women: an interview with Dr. Ladapo, NYU School of Medicine

CGRP monoclonal antibodies show promise in treating migraine

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Low heart rate variability may place women at risk for sexual dysfunction

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Pain News and Research

Latest Pain News and Research

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Newsletters you may be interested in